Marker found for disease progression in MS

Metabolite abnormalities measured via MR spectroscopy can accurately predict brain atrophy and future disability in multiple sclerosis, according to US researchers.

Their study involved comparing levels of N-acetylaspartate (NAA), which is typically reduced in MS patients and myo-inositol (mI, increased in MS) in the normal-appearing white matter of over 300 MS patients and healthy controls.

With four year follow-up, they found that the ratio of NAA to mI predicted brain atrophy and also correlated with greater